Xencor (XNCR) Valuation Check After New Oncology And Autoimmune Pipeline Milestones [Yahoo! Finance]
Xencor, Inc. (XNCR)
Last xencor, inc. earnings: 2/24 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.xencor.com/investor-relations
Company Research
Source: Yahoo! Finance
Xencor (XNCR) shares are under the spotlight after the company outlined 2026 pipeline milestones, including early Phase 1 signals for XmAb819 in renal cell carcinoma and timelines for several planned pivotal studies. See our latest analysis for Xencor. The recent pipeline update arrives after a weaker stretch for the stock, with a 30 day share price return of 17.75% and a 1 year total shareholder return decline of 33.52%, suggesting momentum has been fading despite ongoing clinical progress. If Xencor has piqued your interest in this corner of the market, it can be useful to compare it with other healthcare stocks that are shaping the future of medicine. With Xencor's shares down 33.52% over the past year and trading at a discount to the average analyst price target, the key question is whether this weakness signals an undervalued pipeline or a market that has already priced in future growth. Compared with Xencor's last close of US$12.79, the most followed narrative assigns
Show less
Read more
Impact Snapshot
Event Time:
XNCR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XNCR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XNCR alerts
High impacting Xencor, Inc. news events
Weekly update
A roundup of the hottest topics
XNCR
News
- Xencor Highlights Corporate Priorities and 2026 Pipeline MilestonesBusiness Wire
- Incyte marks late-stage trial win for Xencor-partnered lymphoma therapy [Seeking Alpha]Seeking Alpha
- Xencor: Fortress Balance Sheet Bodes Well For XmAb819 And XmAb942 [Seeking Alpha]Seeking Alpha
- Calculating The Fair Value Of Xencor, Inc. (NASDAQ:XNCR) [Yahoo! Finance]Yahoo! Finance
- Xencor (NASDAQ:XNCR) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
XNCR
Earnings
- 11/5/25 - Beat
XNCR
Sec Filings
- 1/8/26 - Form 8-K
- 12/23/25 - Form 4
- 12/23/25 - Form 4
- XNCR's page on the SEC website